ANAB

MKT CAP:$2B

AnaptysBio, Inc.

Market Cap

$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$51.74+$6.79 (+15.11%)

Apr 23, 2026

Company Details

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 ...

CEO

Daniel R. Faga

IPO Date

Jan 26, 2017

Website

www.anaptysbio.com

Key Metrics TTM

Revenue

$235M

+157.0% YoY

Net Income

-$13M

EPS (Diluted)

-$0.52

Free Cash Flow

$20M

Revenue / Share

$7.49

Gross Margin

99.0%

Operating Margin

20.4%

Net Margin

-5.6%

FCF Margin

8.4%

P/S

9.8x

P/E

—

Earnings Reports

Q1 2026

May 4, 2026

PENDING

Q4 2025

Mar 3, 2026

$108M+151.1%EPS $1.58

Q3 2025

Nov 4, 2025

$76M+154.3%EPS $0.52

Q2 2025

Aug 6, 2025

$22M+102.9%EPS -$1.34

Q1 2025

May 5, 2025

$28M+286.8%EPS -$1.28

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$970.0K	-$22M	-$32M
Q2 22	$1M	-$20M	-$28M
Q3 22	$1M	-$21M	-$30M
Q4 22	$7M	-$17M	-$26M
Q1 23	$1M	-$34M	-$44M
Q2 23	$3M	-$29M	-$40M
Q3 23	$3M	-$28M	-$38M
Q4 23	$9M	-$25M	-$42M
Q1 24	$7M	-$30M	-$42M
Q2 24	$11M	-$31M	-$40M
Q3 24	$30M	-$12M	-$23M
Q4 24	$43M	$524.0K	-$10M
Q1 25	$28M	-$13M	-$28M
Q2 25	$22M	-$16M	-$26M
Q3 25	$76M	$45M	$35M
Q4 25	$108M	$216M	$67M

Valuation

Quarter	P/S	P/E
Q1 22	43.3x	—
Q2 22	95.2x	—
Q3 22	510.5x	—
Q4 22	222.8x	—
Q1 23	214.4x	—
Q2 23	177.2x	—
Q3 23	153.2x	—
Q4 23	133.6x	—
Q1 24	99.8x	—
Q2 24	75.2x	—
Q3 24	40.1x	—
Q4 24	25.1x	—
Q1 25	20.5x	—
Q2 25	18.6x	—
Q3 25	13.5x	—
Q4 25	9.8x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$21M	-$21M
Q2 22	-$24M	-$24M
Q3 22	-$18M	-$18M
Q4 22	-$11M	-$11M
Q1 23	-$25M	-$25M
Q2 23	-$25M	-$26M
Q3 23	-$36M	-$37M
Q4 23	-$34M	-$35M
Q1 24	-$37M	-$37M
Q2 24	-$21M	-$21M
Q3 24	-$10M	-$10M
Q4 24	-$67M	-$67M
Q1 25	-$11M	-$11M
Q2 25	-$40M	-$40M
Q3 25	-$27M	-$27M
Q4 25	$98M	$98M

Capital Expenditures

Quarter	CapEx
Q1 22	$55.0K
Q2 22	$78.0K
Q3 22	$50.0K
Q4 22	$175.0K
Q1 23	$175.0K
Q2 23	$190.0K
Q3 23	$162.0K
Q4 23	$280.0K
Q1 24	$27.0K
Q2 24	$33.0K
Q3 24	$35.0K
Q4 24	$263.0K
Q1 25	$35.0K
Q2 25	$39.0K
Q3 25	$12.0K
Q4 25	$1.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-91.4%	+10.5%
Q2 22	-96.0%	-5.1%
Q3 22	-93.8%	+11.8%
Q4 22	+573.4%	+1.9%
Q1 23	+41.6%	+39.9%
Q2 23	+184.5%	+50.3%
Q3 23	+156.6%	+32.7%
Q4 23	+32.3%	+56.0%
Q1 24	+422.5%	+7.9%
Q2 24	+217.1%	+17.6%
Q3 24	+804.7%	+28.6%
Q4 24	+378.8%	+3.2%
Q1 25	+286.8%	+12.0%
Q2 25	+102.9%	-5.6%
Q3 25	+154.3%	-21.1%
Q4 25	+151.1%	-21.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$8M	798.1%
Q2 22	$7M	547.5%
Q3 22	$6M	485.0%
Q4 22	$7M	98.2%
Q1 23	$9M	644.8%
Q2 23	$8M	243.6%
Q3 23	$8M	235.3%
Q4 23	$8M	90.1%
Q1 24	$10M	141.1%
Q2 24	$8M	68.8%
Q3 24	$8M	27.3%
Q4 24	$8M	19.0%
Q1 25	$9M	33.0%
Q2 25	$9M	41.5%
Q3 25	$9M	12.0%
Q4 25	$9M	7.9%

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$23M	$7M
Q2 22	$21M	$8M
Q3 22	$22M	$9M
Q4 22	$23M	$9M
Q1 23	$35M	$11M
Q2 23	$33M	$11M
Q3 23	$31M	$10M
Q4 23	$41M	$10M
Q1 24	$37M	$12M
Q2 24	$42M	$9M
Q3 24	$42M	$11M
Q4 24	$43M	$10M
Q1 25	$41M	$14M
Q2 25	$38M	$11M
Q3 25	$31M	$10M
Q4 25	$26M	$16M

Revenue Segments

Quarter	Research and Development Segment
Q1 25	$28M
Q2 25	$22M
Q3 25	$76M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$166M	$339M	$506M
Q2 22	$72M	$370M	$442M
Q3 22	$59M	$384M	$443M
Q4 22	$71M	$370M	$441M
Q1 23	$95M	$337M	$431M
Q2 23	$35M	$394M	$429M
Q3 23	$26M	$387M	$413M
Q4 23	$36M	$355M	$391M
Q1 24	$54M	$301M	$355M
Q2 24	$72M	$279M	$351M
Q3 24	$192M	$239M	$430M
Q4 24	$123M	$262M	$385M
Q1 25	$99M	$241M	$340M
Q2 25	$44M	$221M	$266M
Q3 25	$110M	$139M	$249M
Q4 25	$238M	$73M	$312M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	28M	+0.7%	+1.3%
Q2 22	28M	+1.8%	+3.0%
Q3 22	28M	+0.3%	+3.1%
Q4 22	28M	+0.6%	+3.3%
Q1 23	28M	-1.7%	+0.9%
Q2 23	27M	-4.7%	-5.6%
Q3 23	27M	-0.3%	-6.2%
Q4 23	27M	+0.2%	-6.5%
Q1 24	27M	+0.8%	-4.1%
Q2 24	27M	+2.1%	+2.7%
Q3 24	29M	+5.6%	+8.8%
Q4 24	30M	+5.4%	+14.5%
Q1 25	31M	+0.6%	+14.3%
Q2 25	29M	-6.0%	+5.3%
Q3 25	29M	+0.7%	+0.4%
Q4 25	31M	+8.0%	+2.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$9.5K	102
Q2 22	$11.9K	102
Q3 22	$12.7K	102
Q4 22	$70.9K	96
Q1 23	$14.3K	96
Q2 23	$36.0K	96
Q3 23	$34.6K	96
Q4 23	$77.0K	117
Q1 24	$61.4K	117
Q2 24	$93.8K	117
Q3 24	$256.6K	117
Q4 24	$317.0K	136
Q1 25	$204.2K	136
Q2 25	$163.7K	136
Q3 25	$561.2K	136
Q4 25	$1M	104

Revenue / Employee